LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
36 funds hold it
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 6, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.45 expected
Estimates as of Nov 13, 2026
EPS expected
$0.41 to $0.49
Revenue expected
8 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 6, 2026 | $0.44est. $0.45 | -1.71%miss | $299.7MSEC filing | +4.6%from $286.6M |
| Jun 30, 2026Reported Aug 12, 2026 | $0.52est. $0.52 | +0.13%in line | $321.2MAlpha Vantage | +1.3%from $317.0M |
| Mar 31, 2026Reported May 6, 2026 | $0.53est. $0.53 | -0.82%in line | $311.4MSEC filing | -1.5%from $316.2M |
| Dec 31, 2025Reported Feb 4, 2026 | $0.46est. $0.43 | +5.84%beat | $295.9MSEC filing | -0.4%from $297.0M |
| Sep 30, 2025Reported Nov 5, 2025 | $0.36est. $0.36 | +0.00%in line | $286.6MSEC filing | -1.0%from $289.5M |
| Jun 30, 2025Reported Aug 6, 2025 | $0.53est. $0.50 | +6.00%beat | $317.0MAlpha Vantage | +3.5%from $306.1M |
| Mar 31, 2025Reported May 7, 2025 | $0.56est. $0.51 | +9.80%beat | $316.2MSEC filing | +4.2%from $303.4M |
| Dec 31, 2024Reported Feb 5, 2025 | $0.42est. $0.39 | +7.69%beat | $297.0MSEC filing | +9.0%from $272.6M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $295.9M | $311.4M | $321.2M | $299.7M |
| Cost of what it sold | $104.6M | $103.1M | $109.8M | $103.1M |
| Gross profit | $191.3M | $208.3M | $211.4M | $196.6M |
| What it spent | ||||
| Research and development | $23.1M | $23.5M | $23.9M | $26.3M |
| Sales and admin | $113.7M | $109.3M | $113.2M | $133.7M |
| Total operating expenses | $136.8M | $132.8M | $137.1M | $160.0M |
| What was left | ||||
| Operating profit | $54.5M | $75.5M | $74.3M | $36.6M |
| Interest on debt | $2.2M | $3.2M | $2.9M | $2.2M |
| Profit before tax | $50.8M | $71.2M | $70.7M | $34.7M |
| Tax | $12.8M | $20.2M | $16.1M | $6.4M |
| Net profit | $38.0M | $51.1M | $54.6M | $28.3M |
| EBITDA | $77.7M | $98.6M | $91.9M | $60.6M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
BullishNov 9What Bio-Techne Doubters Overlooked
NeutralNov 7Bio-Techne 3Q 2026: Revenue $299.71M, EPS $0.18 — 10-Q Summary
Leans bearishNov 6Sales rise 5% at Bio-Techne (TECH), but quarterly earnings move the other way.
NeutralNov 6FMR LLC and Abigail P. Johnson Report 0.7% Stake in Bio-Techne Corp via 13G Amendment
NeutralNov 5BIO-TECHNE DECLARES DIVIDEND
NeutralNov 5Bio-Techne (TECH) Stock Trades Above Fair Value On Cash Flow Estimates
Leans bearishNov 4Bio-Techne earnings missed by $0.03, revenue fell short of estimates
BearishNov 424 macro signals shaping TECH right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
